Abstract
Allogeneic stem cell transplantation (allo-SCT) is a curative option for patients with relapsed follicular lymphoma (FL). Prospective studies of reduced-intensity conditioning (RIC) have revealed that chemosensitivity at allo-SCT is the most reliable predictor of outcome; however, limited data are available for progressive/refractory disease. We report here a retrospective analysis of RIC allo-SCT for patients with FL. The purpose of this study was to elucidate the role of allo-SCT for patients with relapsed/refractory FL. We analyzed 46 patients - 11 (24%) transplanted in CR, 6 (13%) transplanted in PR and 29 (63%) with progressive/refractory disease. The estimated 5-year overall survival rate was 71.6% (95% confidence interval (CI), 51.5-84.5%). According to the disease status at transplantation, the 5-year survival rate was 80.7% (95% CI, 37.7-95.4%) in the patients with CR or PR and 66.1% (95% CI, 41.5-82.3%) in those with progressive/refractory disease (P=0.29). There were no differences in relapse/progression and non-relapse mortality between the patients with chemosensitive disease and progressive/refractory disease. Allo-SCT may be a valuable treatment option, even for patients with progressive/refractory FL.
| Original language | English |
|---|---|
| Pages (from-to) | 1299-1305 |
| Number of pages | 7 |
| Journal | Bone Marrow Transplantation |
| Volume | 50 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - 2015 Oct 1 |
Fingerprint
ASJC Scopus subject areas
- Hematology
- Transplantation
Cite this
Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma. / Yano, S.; Mori, Takehiko; Kanda, Y.; Kato, Jun; Nakaseko, C.; Fujisawa, S.; Tomita, N.; Sakai, R.; Shono, K.; Saitoh, T.; Aotsuka, N.; Kobayashi, N.; Saito, T.; Takahashi, S.; Kanamori, H.; Okamoto, Shinichiro.
In: Bone Marrow Transplantation, Vol. 50, No. 10, 01.10.2015, p. 1299-1305.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma
AU - Yano, S.
AU - Mori, Takehiko
AU - Kanda, Y.
AU - Kato, Jun
AU - Nakaseko, C.
AU - Fujisawa, S.
AU - Tomita, N.
AU - Sakai, R.
AU - Shono, K.
AU - Saitoh, T.
AU - Aotsuka, N.
AU - Kobayashi, N.
AU - Saito, T.
AU - Takahashi, S.
AU - Kanamori, H.
AU - Okamoto, Shinichiro
PY - 2015/10/1
Y1 - 2015/10/1
N2 - Allogeneic stem cell transplantation (allo-SCT) is a curative option for patients with relapsed follicular lymphoma (FL). Prospective studies of reduced-intensity conditioning (RIC) have revealed that chemosensitivity at allo-SCT is the most reliable predictor of outcome; however, limited data are available for progressive/refractory disease. We report here a retrospective analysis of RIC allo-SCT for patients with FL. The purpose of this study was to elucidate the role of allo-SCT for patients with relapsed/refractory FL. We analyzed 46 patients - 11 (24%) transplanted in CR, 6 (13%) transplanted in PR and 29 (63%) with progressive/refractory disease. The estimated 5-year overall survival rate was 71.6% (95% confidence interval (CI), 51.5-84.5%). According to the disease status at transplantation, the 5-year survival rate was 80.7% (95% CI, 37.7-95.4%) in the patients with CR or PR and 66.1% (95% CI, 41.5-82.3%) in those with progressive/refractory disease (P=0.29). There were no differences in relapse/progression and non-relapse mortality between the patients with chemosensitive disease and progressive/refractory disease. Allo-SCT may be a valuable treatment option, even for patients with progressive/refractory FL.
AB - Allogeneic stem cell transplantation (allo-SCT) is a curative option for patients with relapsed follicular lymphoma (FL). Prospective studies of reduced-intensity conditioning (RIC) have revealed that chemosensitivity at allo-SCT is the most reliable predictor of outcome; however, limited data are available for progressive/refractory disease. We report here a retrospective analysis of RIC allo-SCT for patients with FL. The purpose of this study was to elucidate the role of allo-SCT for patients with relapsed/refractory FL. We analyzed 46 patients - 11 (24%) transplanted in CR, 6 (13%) transplanted in PR and 29 (63%) with progressive/refractory disease. The estimated 5-year overall survival rate was 71.6% (95% confidence interval (CI), 51.5-84.5%). According to the disease status at transplantation, the 5-year survival rate was 80.7% (95% CI, 37.7-95.4%) in the patients with CR or PR and 66.1% (95% CI, 41.5-82.3%) in those with progressive/refractory disease (P=0.29). There were no differences in relapse/progression and non-relapse mortality between the patients with chemosensitive disease and progressive/refractory disease. Allo-SCT may be a valuable treatment option, even for patients with progressive/refractory FL.
UR - http://www.scopus.com/inward/record.url?scp=84943422621&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84943422621&partnerID=8YFLogxK
U2 - 10.1038/bmt.2015.158
DO - 10.1038/bmt.2015.158
M3 - Article
C2 - 26168068
AN - SCOPUS:84943422621
VL - 50
SP - 1299
EP - 1305
JO - Bone Marrow Transplantation
JF - Bone Marrow Transplantation
SN - 0268-3369
IS - 10
ER -